Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms
/ diagnostic imaging
Carcinoma, Hepatocellular
/ diagnostic imaging
Cholangiocarcinoma
/ diagnostic imaging
Female
Humans
Liver
/ diagnostic imaging
Liver Neoplasms
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Middle Aged
Multidetector Computed Tomography
Neoplasms, Multiple Primary
/ diagnostic imaging
Retrospective Studies
Tumor Burden
combined hepatocellular-cholangiocarcinoma
hepatocellular carcinoma
magnetic resonance imaging
multidetector computed tomography
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
28 05 2020
28 05 2020
Historique:
received:
06
02
2020
accepted:
22
04
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
13
7
2021
Statut:
epublish
Résumé
Background The aim of the study was to investigate the performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) identifying the features that allow an accurate characterization. Patients and methods Sixty-two patients (median age, 63 years; range, 38-80 years), with pre-surgical biopsy diagnosis of hepatocellular carcinoma (HCC) that underwent hepatic resection, comprised our retrospective study. All patients were subject to multidetector computed tomography (MDCT); 23 patients underwent to magnetic resonance (MR) study. The radiologist reported the presence of the HCC by using LIRADS v2018 assessing major and ancillary features. Results Final histological diagnosis was HCC for 51 patients and cHCC-CCA for 11 patients. The median nodule size was 46.0 mm (range 10-190 mm). For cHCC-CCA the median size was 33.5 mm (range 20-80 mm), for true HCC the median size was 47.5 mm (range 10-190 mm). According to LIRADS categories: 54 (87.1%) nodules as defined as LR-5, 1 (1.6%) as LR-3, and 7 (11.3%) as LR-M. Thirty-nine nodules (63%) showed hyper-enhancement in arterial phase; among them 4 were cHCC-CCA (36.4% of cHCC-CCA) and 35 (68.6%) true HCC. Forty-three nodules (69.3%) showed washout appearance; 6 cHCC-CCAs (54.5% of cHCC-CCA) and 37 true HCC (72.5%) had this feature. Only two cHCC-CCA patients (18.2% of cHCC-CCA) showed capsule appearance. Five cHCC-CCA (71.4% of cHCC-CCA) showed hyperintensity on T2-W sequences while two (28.6%) showed inhomogeneous signal in T2-W. All cHCC-CCA showed restricted diffusion. Seven cHCC-CCA patients showed a progressive contrast enhancement and satellite nodules. Conclusions The presence of satellite nodules, hyperintense signal on T2-W, restricted diffusion, the absence of capsule appearance in nodule that shows peripheral and progressive contrast enhancement are suggestive features of cHCC-CCA.
Identifiants
pubmed: 32463393
doi: 10.2478/raon-2020-0029
pii: /j/raon.2020.54.issue-2/raon-2020-0029/raon-2020-0029.xml
pmc: PMC7276649
doi:
pii:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-158Références
Eur Radiol. 2019 May;29(5):2408-2416
pubmed: 30552477
Liver Transpl. 2014 Aug;20(8):952-9
pubmed: 24777610
Eur Radiol. 2019 Jan;29(1):373-382
pubmed: 29955948
Infect Agent Cancer. 2018 Jul 3;13:23
pubmed: 29988667
Oncotarget. 2016 Nov 29;7(48):79357-79364
pubmed: 27764817
Cancer Imaging. 2018 Feb 27;18(1):8
pubmed: 29486800
World J Gastroenterol. 2014 Sep 21;20(35):12615-20
pubmed: 25253966
AJR Am J Roentgenol. 2016 Jul;207(1):25-31
pubmed: 26866746
Am J Pathol. 1949 Jul;25(4):647-55
pubmed: 18152860
AJR Am J Roentgenol. 2011 Jun;196(6):W758-65
pubmed: 21606265
J Gastroenterol Hepatol. 2002 Apr;17(4):401-5
pubmed: 11982719
Infect Agent Cancer. 2017 Apr 28;12:23
pubmed: 28465718
J Gastroenterol Hepatol. 2010 Sep;25(9):1485-92
pubmed: 20796144
Am J Surg Pathol. 2013 Apr;37(4):496-505
pubmed: 23388123
Cancer. 1954 May;7(3):462-503
pubmed: 13160935
J Gastrointest Surg. 2016 Feb;20(2):411-20
pubmed: 26628072
Ann Surg Oncol. 2008 Jul;15(7):1880-90
pubmed: 18443881
Oncotarget. 2017 Apr 19;8(31):51224-51237
pubmed: 28881643
AJR Am J Roentgenol. 2013 Aug;201(2):332-9
pubmed: 23883213
Radiol Med. 2016 Feb;121(2):122-31
pubmed: 26345332
World J Hepatol. 2017 Feb 28;9(6):300-309
pubmed: 28293379
Korean J Radiol. 2015 Jan-Feb;16(1):50-68
pubmed: 25598674
World J Gastroenterol. 2014 Sep 21;20(35):12628-36
pubmed: 25253968
Abdom Imaging. 2012 Apr;37(2):215-30
pubmed: 21909721